These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 15570634

  • 21. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial.
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [Abstract] [Full Text] [Related]

  • 22. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [Abstract] [Full Text] [Related]

  • 23. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 24. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
    Westhovens R, Houssiau F, Joly J, Everitt DE, Zhu Y, Sisco D, Van Hartingsveldt B, Mascelli MA, Graham MA, Durez P, Bouman-Thio E.
    J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
    [Abstract] [Full Text] [Related]

  • 25. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, White B, Giannini EH, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
    [Abstract] [Full Text] [Related]

  • 26. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 27. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study.
    Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, Helfgott SM, Leff JA, Weinblatt ME.
    J Rheumatol; 2006 Apr; 33(4):659-64. PubMed ID: 16482646
    [Abstract] [Full Text] [Related]

  • 28. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
    Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R.
    Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
    [Abstract] [Full Text] [Related]

  • 29. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P, Levine M, Gaebel K, Thabane L.
    Can J Clin Pharmacol; 2005 Apr; 12(3):e254-63. PubMed ID: 16278497
    [Abstract] [Full Text] [Related]

  • 30. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF.
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [Abstract] [Full Text] [Related]

  • 31. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 32. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P, Skogh T.
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [Abstract] [Full Text] [Related]

  • 33. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
    Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, Cohen SB, Gangnon RE, Schiff MH.
    J Rheumatol; 2004 Jun; 31(6):1098-102. PubMed ID: 15170921
    [Abstract] [Full Text] [Related]

  • 34. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P, 20000223 Study Group.
    Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
    [Abstract] [Full Text] [Related]

  • 35. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

  • 36. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.
    Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW.
    J Rheumatol; 2006 May; 33(5):854-61. PubMed ID: 16541481
    [Abstract] [Full Text] [Related]

  • 37. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
    van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Pedersen R, Freundlich B, Fatenejad S.
    Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
    [Abstract] [Full Text] [Related]

  • 38. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.
    Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O.
    Ann Rheum Dis; 2007 Jul; 66(7):893-9. PubMed ID: 17412737
    [Abstract] [Full Text] [Related]

  • 39. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
    Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B.
    J Rheumatol; 2006 Feb; 33(2):234-43. PubMed ID: 16465653
    [Abstract] [Full Text] [Related]

  • 40. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA.
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.